GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

51

Low-Dose Aspirin for Lynch Syndrome: Lancet | July 2026

Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an...

52

4-Year Benefit of Durvalumab in BTC: JAMA Oncol | July 2026

Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term...

53

The First Standardized PET Response Framework for Neuroendocrine Tumors: The Lancet Oncology | July 2026

Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment...

54

Staging Laparoscopy in Gastric Cancer: Annals of Surgical Oncology | July 2026

Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains...

55

Celecoxib Boosts Neoadjuvant Immunotherapy in dMMR/MSI-H CRC : Lancet Oncol | Jul 2026

Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence...

56

Cancer Cachexia: Science | July 2026

Introduction: Cancer-associated cachexia is a devastating syndrome characterized by loss of appetite, weight loss, and muscle wasting, affecting up to half of patients with lung cancer. This landmark...

57

Liquid Biopsy-Guided Cetuximab Rechallenge in mCRC: ESMO GI Cancers Congress | July 2026

Introduction: Resistance to anti-EGFR therapy has traditionally been considered irreversible in metastatic colorectal cancer (mCRC). However, emerging evidence suggests that resistance is dynamic and can be monitored using...

58

PD-(L)1 Inhibitors Plus Chemotherapy in Advanced Gastric Cancer: CGH | July 2026

Introduction: Immune checkpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced HER2-negative gastric and gastroesophageal junction cancers. This meta-analysis evaluated whether treatment benefits differ...

59

CLDN18.2 and Gastric Cancer: Cancer Letters | July 2026

Introduction: The treatment of advanced gastric cancer is rapidly evolving from conventional chemotherapy to biomarker-driven precision medicine. Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed in gastric...

60

Pemigatinib Outperforms Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma : JCO | June 2026

Introduction: Cholangiocarcinoma is an aggressive biliary tract malignancy with limited treatment options and poor long-term outcomes. The discovery of fibroblast growth factor receptor 2 (FGFR2) rearrangements in a...

Previous
156720
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer